# FOXP3

Source: https://onco.cc/targets/foxp3/  
OnCo record `foxp3` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FOXP3 (Forkhead box protein P3) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.

## Summary

Transcriptional regulator which is crucial for the development and inhibitory function of regulatory T-cells (Treg). Plays an essential role in maintaining homeostasis of the immune system by allowing the acquisition of full suppressive function and stability of the Treg lineage, and by directly modulating the expansion and function of conventional T-cells. Can act either as a transcriptional repressor or a transcriptional activator depending on its interactions with other transcription factors, histone acetylases and deacetylases.

CIViC holds 1 clinical evidence item and 0 assertions across 2 variants, naming Epirubicin.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: forkhead box P3; Forkhead box protein P3; JM2; DIETER; SCURFIN
- Tags: cancer-genes-wave
- Symbol: FOXP3
- Class: transcription
- Biology: Transcriptional regulator which is crucial for the development and inhibitory function of regulatory T-cells (Treg). Plays an essential role in maintaining homeostasis of the immune system by allowing the acquisition of full suppressive function and stability of the Treg lineage, and by directly modulating the expansion and function of conventional T-cells. Can act either as a transcriptional repressor or a transcriptional activator depending on its interactions with other transcription factors, histone acetylases and deacetylases. The suppressive activity of Treg involves the coordinate activation of many genes, including CTLA4 and TNFRSF18 by FOXP3 along with repression of genes encoding cytokines such as interleukin-2 (IL2) and interferon-gamma (IFNG). Inhibits cytokine production and T-cell effector function by repressing the activity of two key transcription factors, RELA and NFATC2. Mediates transcriptional repression of IL2 via its association with histone acetylase KAT5 and histone deacetylase HDAC7. Location: Nucleus; Cytoplasm (UniProt). Locus Xp11.23 (HGNC).
- Where found: Breast cancer: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:6106: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6106
- UniProt Q9BZS1: https://www.uniprot.org/uniprotkb/Q9BZS1/entry
- NCBI Gene 50943: https://www.ncbi.nlm.nih.gov/gene/50943
- Ensembl ENSG00000049768: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000049768

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)

---
JSON: https://onco.cc/api/v1/entities/foxp3.json